# NCT06521567 (NCT06521567)

> A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06521567
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinsic Pontine Glioma (DIPG); Ependymoma; Osteosarcoma; Hepatic Tumors; Hepatoblastoma; Hepatocellular Carcinoma (HCC); Fibrolamellar Carcinoma; Rhabdomyosarcoma
- Interventions: Cobolimab; Dostarlimab
- Enrollment: 83
- Primary outcome: Part 1- Number of participants with Dose Limiting Toxicities (DLTs)
- Primary outcome: Part 1- Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs) and adverse events (AEs) leading to discontinuation occurring during the study
- Primary outcome: Part 1- Serum concentration of Cobolimab
- Primary outcome: Part 1- Serum concentration of Dostarlimab
- Primary outcome: Part 1- Recommended Phase 2 Dose (RP2D) of Cobolimab and Dostarlimab combination
- Primary outcome: Part 2- Confirmed Objective Response Rate (ORR)
- Primary outcome: Part 2- Number of participants with TEAEs, SAEs, imAEs, TEAEs leading to death and AEs leading to discontinuation
- Primary outcome: Part 2-Number of participants with changes in laboratory parameters, vital signs and cardiac parameters

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 2
- Podcasts: 1
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06521567